Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers

Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers

Abstract Background To include the patient perspective in the assessment of adverse events in oncology, a patient-reported outcomes (PRO) version of the Common Terminology Criteria for Adverse Events (CTCAE) was developed by the US National Cancer Institute, the so called PRO-CTCAE. The objective of...

Podrobná bibliografie
Hlavní autoři:	Maximilian Günther, Leopold Hentschel, Markus Schuler, Theresa Müller, Katharina Schütte, Yon-Dschun Ko, Ingo Schmidt-Wolf, Ulrich Jaehde
Médium:	Článek
Jazyk:	English
Vydáno:	BMC 2023-07-01
Edice:	BMC Cancer
Témata:	Patient-reported outcomes PRO-CTCAE Breast cancer Symptom burden Multiple myeloma Prostate cancer
On-line přístup:	https://doi.org/10.1186/s12885-023-11115-7

Podobné jednotky

A multi-method approach to selecting PRO-CTCAE symptoms for patient-reported outcome in women with endometrial or ovarian cancer undergoing chemotherapy
Autor: Mille Guldager Christiansen, a další
Vydáno: (2023-07-01)

Establishing a common metric for patient-reported outcomes in cancer patients: linking patient reported outcomes measurement information system (PROMIS), numerical rating scale, and patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
Autor: Minji K. Lee, a další
Vydáno: (2020-12-01)

Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients
Autor: Christina Baeksted, a další
Vydáno: (2017-09-01)

Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Autor: Tian Qi Wang, a další
Vydáno: (2018-10-01)

Dutch translation and linguistic validation of the U.S. National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)
Autor: Evalien Veldhuijzen, a další
Vydáno: (2020-10-01)

Clinician and Patient Reporting of Symptomatic Adverse Events in Cancer Clinical Trials: Using CTCAE and PRO-CTCAE® to Provide Two Distinct and Complementary Perspectives
Autor: Minasian LM, a další
Vydáno: (2022-12-01)

Swahili translation and cultural adaptation of the pediatric patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
Autor: Kristin M. Schroeder, a další
Vydáno: (2023-06-01)

Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Autor: Tempei Miyaji, a další
Vydáno: (2017-12-01)

A study demonstrating users’ preference for the adapted-REQUITE patient-reported outcome questionnaire over PRO-CTCAE® in patients with lung cancer
Autor: Thomas Jordan, a další
Vydáno: (2024-04-01)

Score equivalence of paper-, tablet-, and interactive voice response system-based versions of PROMIS, PRO-CTCAE, and numerical rating scales among cancer patients
Autor: Minji K. Lee, a další
Vydáno: (2021-09-01)

Psychometric properties of patient-reported outcomes Common Terminology Criteria for adverse events (PRO-CTCAE®) in breast cancer patients: The prospective observational multicenter VIP study
Autor: Caterina Caminiti, a další
Vydáno: (2024-10-01)

Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events
Autor: Shan-Shan Yang, a další
Vydáno: (2021-07-01)

Evaluating the use of the EORTC patient-reported outcome measures for improving inter-rater reliability of CTCAE ratings in a mixed population of cancer patients: study protocol for a randomized controlled trial
Autor: Lisa M. Wintner, a další
Vydáno: (2020-10-01)

Patient-reported outcomes for patients with breast cancer undergoing radiotherapy: A single-center registry experience
Autor: Brady S. Laughlin, a další
Vydáno: (2022-08-01)

Months and Severity Score (MOSES) in a Phase III trial (PARCER): A new comprehensive method for reporting adverse events in oncology clinical trials
Autor: Nilesh Ranjan, a další
Vydáno: (2022-05-01)

Identifying symptomatic adverse events using the patient‐reported outcomes version of the common terminology criteria for adverse events in patients with non‐small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations
Autor: Yanyan Zhu, a další
Vydáno: (2023-03-01)

Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy
Autor: Lærke K. Tolstrup, a další
Vydáno: (2019-03-01)

Use of the National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events to assess treatment tolerability in pulmonary arterial hypertension: qualitative patient research findings in current and former users of oral selexipag
Autor: Stacy Davis, a další
Vydáno: (2023-12-01)

Determining the safety of ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: A toxicity assessment of 150 patients
Autor: Marieke van Son, M.D., a další
Vydáno: (2021-03-01)

Side effects of steroid-sparing agents in patients with bullous pemphigoid and pemphigus: A systematic reviewCapsule Summary
Autor: Faith A.P. Zeng, a další
Vydáno: (2022-12-01)

Visualizing adverse events in clinical trials using correspondence analysis with R-package visae
Autor: Márcio A. Diniz, a další
Vydáno: (2021-11-01)

Effect of acupuncture in prevention and treatment of chemotherapy-induced nausea and vomiting in patients with advanced cancer: study protocol for a randomized controlled trial
Autor: Qi-wei Li, a další
Vydáno: (2017-04-01)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
Autor: Agnese Barnabei, a další
Vydáno: (2022-03-01)

Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients
Autor: Shah, V, a další
Vydáno: (2020)

Assessing concordance between patient-reported and investigator-reported CTCAE after proton beam therapy for prostate cancer
Autor: Roman O. Kowalchuk, a další
Vydáno: (2021-11-01)

Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022
Autor: Marwan A. Alrasheed, a další
Vydáno: (2024-06-01)

Myeloma and Cystoisospora belli
Autor: Pathum Sookaromdee, a další
Vydáno: (2021-08-01)

A Case Report of Multiple Myeloma Concurrent with Gastric Adenocarcinoma
Autor: Marziyeh Ghalamkari, a další
Vydáno: (2022-07-01)

Case Report: Pulmonary Kaposi Sarcoma in a non-HIV patient [version 1; referees: 2 approved]
Autor: Arber Kodra, a další
Vydáno: (2015-10-01)

Rituximab efficiently depletes B cells in lung tumors and normal lung tissue [version 1; referees: 2 approved]
Autor: Albane Joly-Battaglini, a další
Vydáno: (2016-01-01)

Medication risks in older patients (70 +) with cancer and their association with therapy-related toxicity
Autor: Imke Ortland, a další
Vydáno: (2022-08-01)

Impact of M‐protein detection on the response evaluations of patients undergoing treatment with the IgG‐κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents
Autor: Yuko Shirouchi, a další
Vydáno: (2024-08-01)

Clinical profile of patients with cardiac amyloidosis in India
Autor: Bishav Mohan, a další
Vydáno: (2023-01-01)

Effect of an Inpatient Rehabilitation Program for Recovery of Deconditioning in Hematologic Cancer Patients After Chemotherapy
Autor: Seungwoo Cha, a další
Vydáno: (2018-12-01)

Gallbladder Metastases: A Report of Two Cases
Autor: Mohamad Mouchli, a další
Vydáno: (2019-03-01)

Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
Autor: Diego Acosta-Alvear, a další
Vydáno: (2015-09-01)

CYTOKINE REGULATION IN THE COURSE OF MULTIPLE MYELOMA PROGRESSION
Autor: O. V. Smirnova, a další
Vydáno: (2015-06-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
Autor: Aiken Dao, a další
Vydáno: (2022-12-01)

Implementation of patient-reported outcomes for symptom management in oncology practice through the SIMPRO research consortium: a protocol for a pragmatic type II hybrid effectiveness-implementation multi-center cluster-randomized stepped wedge trial
Autor: Michael J. Hassett, a další
Vydáno: (2022-06-01)

Using a multi-omics approach to identify novel targets in multiple myeloma
Autor: James-Bott, A
Vydáno: (2022)